Towards Healthcare

Inhalable Biologics Companies, Innovation and Organizational Growth 2026

Date : 23 February 2026

Who are the Inhalable Biologics Market Top Vendors and What are Their Offerings?

Inhalable Biologics Market Companies are AstraZeneca, GlaxoSmithKline (GSK), MannKind Corporation, Lonza Group, Cipla

Company Profile

Companies Headquarters Inhalable Biologics
AstraZeneca Cambridge, UK Inhaled monoclonal antibodies and biologics
GlaxoSmithKline (GSK) London, UK Ellipta dry powder inhaler platform
MannKind Corporation Danbury, U.S. Offers Afrezza
Lonza Group Basel, Switzerland Provides inhalable biological proteins
Cipla Mumbai, India Offer inhaler devices and biosimilars
Vectura Group Chippenham, UK Inhaled drug delivery for biologics and complex molecules
Aradigm Corporation Hayward, U.S. Inhaled liposomal formulations for severe lung infections and cystic fibrosis
Teva Pharmaceutical Industries Tel Aviv, Israel Digihaler smart devices
Inovio Pharmaceuticals Plymouth Meeting, U.S. DNA-based inhalable vaccines and therapies
Spero Therapeutics Massachusetts, U.S Inhaled antibiotics and biologics

Inhalable Biologics Market Value Chain Analysis

R&D

  • The R&D of the inhalable biologics focuses on the development of advanced particles and technosphere dry powder technology.
  • Key players: AstraZeneca, GlaxoSmithKline, MannKind Corporation.

Clinical Trials and Regulatory Approvals

  • The device-drug deposition patterns, bioequivalence of inhalable biologics, and local lung mucosal safety are evaluated in the clinical trials and regulatory approvals of the inhalable biologics.
  • Key players: AstraZeneca, GlaxoSmithKline, MannKind Corporation.

Patient Support and Services

  • The digital health platforms and connected smart inhalers are provides for the patient support and services for inhalable biologics.
  • Key players: AstraZeneca, GlaxoSmithKline, Teva Pharmaceutical Industries.

Market Growth

The global inhalable biologics market size was estimated at USD 4.51 billion in 2025 and is predicted to increase from USD 5.3 billion in 2026 to approximately USD 22.87 billion by 2035, expanding at a CAGR of 17.64% from 2026 to 2035.

Inhalable Biologics Market Size is USD 5.3 Billion in 2026.

What are the Recent Developments in the Inhalable Biologics Market?

  • In June 2025, Quattrii, the ‘first ever’ dry powder inhaler (DPI) engine, delivering large volumes of biologic and mRNA molecules, with approximate 70% of the drug in a single inhalation, was launched by Cambridge Healthcare Innovations (CHI).
  • In March 2025, the phase-2 clinical trial of the next-generation, inhaled COVID-19 vaccine was announced to have been initiated by McMaster University, where they will identify the safety of the vaccine in a broad study group.

Now managing your entire Inhalable Biologics Market data is simple - everything in one place. Access the Dashboard

WhatsApp